ProText Mobility Inc (TXTM)

[parabolic2020]

The Truth About TXTM
For years, ProText Mobility, Inc. (TXTM) has been written off as just another penny stock. Critics lined up, calling Dr. J a liar and dismissing every announcement as hype. But here’s the truth: almost every one of his so-called “claims” has since shown up in black-and-white filings. What started as tweets has become official contracts, agreements, and disclosures, and they continue to be added.

The final proof is coming. Once the current filings are PCAOB audited, there will be no more room for doubt, no more excuses, and no more spin. The facts will stand on their own, certified and undeniable. Those who have been paying attention over the past three years already see it. What people laughed at then is now written into legal documents today.

TXTM isn’t just about seeds, it’s about a business model that multiplies value without multiplying debt. It’s about sovereign-backed agreements that protect the company in ways the market still has properly valued. And it’s about building an asset engine powerful enough to change the way agricultural commodities are valued worldwide.
________________________________________
The Critics vs. The Facts
When Dr. J first tweeted about the seeds, critics laughed. They said they were worth ten cents at best. Today, those same seeds anchor an asset base nearing $40 billion, backed by an independent valuation under IFRS and IAS 41 confirming a $16 per seed value.
In 2024, TXTM took the step, one that would later be seen imo as a genius move, of engaging a fully GAAP- and IFRS-compliant auditor, a highly respected firm with a track record of audits for major PCAOB companies including Chevron. That auditor issued the GAAP version of the IFRS audit to OTC Markets, keeping TXTM compliant. Naysayers, in their “infinite wisdom,” assumed Dr. J had made a mistake, claiming the filing was “rejected.” In reality, its sole purpose was to keep TXTM GAAP current, and the IFRS audit, which does not require PCAOB verification, had already validated IAS 41, the biological asset standard that legally set the foundation for the seeds’ true value.

So while the entire U.S. trading platform and investors are waiting on the PCAOB audit and Form 10 to verify, it must be understood that the audits have already been completed under IFRS, because the valuation report could not have been written in the fashion we saw without them. The report that was shown stated the the base value was established by the company in September of 2024 which was the year of the 2024 audited IFRS filing Those audits are accepted worldwide by ,banks, exchanges, and institutions that recognize IFRS outside of GAAP. The $16 valuation is already supported, validated, and respected globally. The rest of the world already knows the work is done. What remains is simply for U.S. exchanges to get the final full picture, which is now in the auditor’s hands to be submitted to the SEC.

While this process unfolded quietly behind the scenes, it is now fully in view: the independent valuator confirmed the stated value, with winterization and genetics identified as the foundational reasons behind that valuation, cementing the fair price as what these seeds are truly worth.
This isn’t speculation, filings prove it. In October 2023, TXTM entered into a Seed Multiplication Agreement:
“On April 6, 2025, the Company delivered 600,000,000 seeds… On June 26, 2025, the Grower returned the original 600,000,000 plus 400,000,000, for a total of 1 billion seeds in inventory.”
And under the Supply Agreement:
“Such that the Company can fulfill orders for its 1,250,000,000 seeds, the Company entered into a Supply Agreement with its President and Chairman of the Board in his capacity as an independent fourth generation farmer…”

That means the seeds are not only multiplying under contract, they already have orders tied to them, with Leeds obligated to purchase at the valuation price.
Because the seeds are valued under IFRS (IAS 41 : Agriculture) and U.S. GAAP (ASC 905 : Agriculture, together with ASC 820 : Fair Value Measurement), their fair value is legally binding for both accounting and contractual purposes. IAS 41 and ASC 905 require biological assets to be measured at fair value less costs to sell, while ASC 820 establishes that related-party transactions must still reflect market-based inputs and observable fair value data. Since Dr. Jamaloodeen holds the valuation report and operates as both Chairman of TXTM and the independent farmer under Leeds, he is bound by fiduciary duty not to disadvantage TXTM. Under corporate law and the arm’s-length principle, transactions between related entities must be executed at fair market value. This means Leeds cannot legally repurchase seeds at a discount, they must be bought back at the documented $16 valuation, ensuring compliance with IFRS, GAAP, and fiduciary obligations between the two separate legal entities.
Once again, what critics called hype has become filings, contracts, and facts.
________________________________________
The Seed Multiplication Program
The Seed Multiplication Program

At the heart of TXTM’s seed asset model is the Seed Multiplication Program, a biological engine that turns every seed into exponential value. Under the agreement, seeds are delivered to Leeds (Dr. J’s farming operation) for planting and germination. At harvest, those seeds are returned to TXTM multiplied, typically at a 4:1 ratio.

For example, in April 2025, TXTM delivered 600 million seeds, and by June 2025 it received back 1 billion seeds — the original 600 million plus 400 million new seeds. Beyond that, under the same program, the company is contractually due approximately another 1.4 billion seeds from that original 600 million seed input. These additional seeds have not yet been booked but are expected to be delivered in subsequent quarters throughout 2025.
In financial terms, the 1.4 billion seeds represent:
Book Value (historical recognition): approximately $505 million, consistent with the values already reported in filings.
Fair Value (independent valuation under IFRS/IAS 41 at $16 per seed): approximately $22.4 billion in additional asset value.

This means TXTM’s assets are not just growing, they are self-replicating, contractually guaranteed, and carrying both recognized book value and massive fair value potential. Unlike traditional companies that rely on debt or heavy infrastructure to scale, TXTM’s inventory grows biologically and legally under enforceable agreements. Every cycle expands the balance sheet without proportional expense, creating an exponential asset engine unmatched in conventional business models.
________________________________________
When you look at history, it usually takes decades and mountains of overhead for the greats to hit a $40 billion asset base:

Microsoft – roughly 32 years, carried by massive R&D budgets in the tens of billions, sprawling engineering campuses, and global sales teams.

Apple – nearly 30 years, weighed down by manufacturing plants, logistics chains across Asia, global retail stores, and some of the highest marketing costs in history.

Intel – more than 20 years, built on multi-billion-dollar semiconductor fabs that required endless reinvestment, high energy costs, and technical labor overhead.

Amazon – 18 years, powered by fulfillment centers, fleets of trucks, distribution warehouses, data centers for AWS, and hundreds of thousands of employees ,all financed with billions in debt and razor-thin margins.

Tesla – the “fast mover,” still needed around 9 years, spending billions on gigafactories, assembly plants, battery production lines, and global dealership/service networks.
Every one of these giants did it the conventional way: issuing shares, piling on debt, building factories, warehouses, data centers, and payrolls they could never shed.

TXTM is the exception.
In less than three years under new management, TXTM has already built a ~$40 billion asset base ,not through debt or dilution, but through a self-replicating biological engine: seeds that multiply under contract.
Debt Advantage: TXTM carries less than $1 million in debt, fully collateralized and secured by former ownership, as disclosed in the filings ,a fraction of what legacy giants carried at the same stage.
No Overhead Drag: TXTM doesn’t build factories or warehouses. Its assets grow biologically, not mechanically. There are no payroll armies or billion-dollar fixed assets to maintain.
Contractual Guarantees: Every seed is tied to binding agreements. Leeds must repurchase seeds at the independently valued $16 fair price under IFRS and GAAP, regardless of whether seeds are planted, processed, or converted into biofuel.
Sovereign Model: With Leeds acting as both supplier and obligated customer, TXTM’s demand is sovereign-style ,guaranteed, infinite, and insulated from Wall Street volatility.
Global Legitimacy: The seeds are booked under IFRS (IAS 41) and GAAP (ASC 905/820), making them liquid and collateralizable in global finance, across currencies.

Where Microsoft built servers, Apple built factories, Intel built fabs, Amazon built warehouses, and Tesla built gigafactories, TXTM built a biological engine.
Every one of its 1.25 billion seeds is a liquid, revenue-generating asset, backed by contract, valued under international accounting standards, and guaranteed a buyer.
No debt. No dilution. No overhead. Just exponential growth..
________________________________________
TXTM's Advantage
The real strategic advantage behind TXTM is Leeds. Through Dr. J, Leeds operates like a sovereign nation, one with the ability to create its own wealth, like printing money, through biological multiplication. In this model, TXTM is the beneficiary. Leeds is both the supplier and the customer: it multiplies the seeds under contract and is obligated to buy them back at full fair value. That creates a closed loop where TXTM is shielded, guaranteed demand, and never exposed to dumping product on an open market.

Dr J.s analogy:. Leeds is the shark, massive, dominant, and unstoppable in its environment. The rest of the industry is the school of fish, swimming in circles, fighting for scraps in traditional markets weighed down by overhead and competition. And in this ecosystem, TXTM becomes the remora fish: small, efficient, and perfectly positioned to feed off the wealth of the shark without ever carrying its burden.
This sovereign alignment gives TXTM global and regional benefits no other company has. It creates a model that scales not just in cannabis, but in agriculture more broadly. The same technology and agreements that drive cannabis seeds can be applied to grains and other biological assets, opening the door to a fully integrated position in the coming global grain exchange. That means TXTM is not only establishing cannabis seeds as a worldwide commodity, but also positioning itself to license and sell patented seed technology, just as Monsanto did with Bayer, locking in value and protecting its genetics under international law.
In short, Leeds gives TXTM something Amazon, Apple, Microsoft, Tesla, and Intel never had: the protection, power, and leverage of a sovereign-scale partner capable of sustaining infinite demand at full fair value.
________________________________________
Shelf Life & Repurchase Agreements

One question skeptics raise is seed shelf life. Seeds generally have about a two-year germination window, which at first glance might suggest limits to long-term value. But that argument collapses under the structure of TXTM’s agreements.

First, the company’s operations are based on a 5,000-hectare farm, of which only 3,000 hectares are currently under cultivation, requiring approximately 15 million seeds per planting per quarter, or about 60 million seeds per year at full scale. Even under this assumption, using only the company’s South African operation, TXTM’s current inventory runs decades ahead of planting requirements.

Second, the Supply Agreement with Leeds eliminates risk: Leeds is contractually obligated to repurchase all seeds at full market value, whether they’re used for planting, processed for oil, or diverted into alternative uses such as biofuel or jet fuel. The valuation does not change with purpose; Leeds must buy them back at the independently established $16 per seed fair value.

This shelf-life concern becomes even weaker when you consider that the above figures reflect only the company’s 5,000-hectare farm, and do not account for additional demand from other farms globally owned by the conglomerate or from cluster farm agreements that have also been publicly mentioned. Those represent future multipliers in demand and revenue that remain above and beyond the baseline farm model.

This means the shelf-life issue is irrelevant. Spoiled seeds don’t become worthless ,they become fuel, stock feed, and various other uses and still must be repurchased from TXTM at full value no ,matter the end product. And because the multiplication program continually “turns over” seed stock, the inventory is never static. It is a constantly regenerating, monetizable asset base.

The current $505 million book value is irrelevant because it does not reflect the true economic reality of TXTM’s assets. Under GAAP, revenue is not limited to simple sales, but also includes the biological appreciation of seeds under ASC 905 and IAS 41, meaning the exponential multiplication of seeds is recognized as real-world asset revenue. On top of that, once a contract is in place, the results of that contract are recognized as revenue even before cash changes hands, because enforceable rights and performance obligations exist.

This is why the hidden value is being overlooked: investors see only the book value today, but the fair value evaluation will capture the true scale. Eventually GAAP will “catch up,” because as seeds move between Leeds and TXTM under binding agreements, that exponential multiplication is converted into valid, auditable revenue. What skeptics miss is that the replication itself carries value, and while it may not yet be fully visible on the balance sheet, it is the engine driving the real-world revenues everyone is waiting to see.

In short: every seed has guaranteed value, every seed has a buyer, and every seed is protected by contract. Shelf life isn’t a weakness — it’s already accounted for, and monetized.
________________________________________
Future Potential
TXTM’s future isn’t limited to cannabis seeds. The model it has built, biological multiplication, sovereign-backed repurchase agreements, and fair-value recognition under IFRS and GAAP, can be applied across agriculture. The same framework can scale into grains, staples, and other biological assets, positioning TXTM to play a central role in the emerging global grain exchange.
Just like Monsanto, later acquired by Bayer, TXTM holds the ability to license its seed technology. That means it won’t just profit from multiplying its own inventory, but from other farmers and entities paying to use its patented genetics. Licensing ensures that value flows not just from sales, but from protecting and monetizing intellectual property, securing long-term revenues under international law.
The model also opens the door to tokenization, converting seeds into digital, tradeable assets that can be listed on both traditional and blockchain exchanges. This bridges agriculture with modern finance, making seeds not just a biological asset but a worldwide commodity class accessible to investors globally.
Put together, this creates a blueprint for TXTM to become a biological Berkshire Hathaway, a diversified powerhouse with assets that grow exponentially, generate returns across multiple sectors, and remain shielded from the burdens of debt and overhead that weighed down every tech giant before it. TXTM isn’t just building a company. It’s building an entirely new asset class.
________________________________________
TXTM is an Emerging Bank
If you think TXTM is only about seeds, you couldn’t be more mistaken. From the beginning, it’s been clear that TXTM is structured as a holding company, with RSAMMDA as a targeted acquisition subsidiary. This was never just about selling seeds, it was about rapidly building legally recognized asset value that could then be leveraged. The seeds are collateral, instantly transferable into liquidity, whether through tokens or cash, enabling acquisitions and real revenue generation in multi-billion-dollar opportunities.
The company itself even stated in its Q2 2025 filing: “The Company has classified its seed inventory as a highly liquid asset, as such seeds can be readily converted into cash, used as collateral, or otherwise monetized under existing agreements.”
TXTM is morphing into a kind of mammoth bank, capable of leveraging and lending against its own balance sheet to institutions worldwide. That is the scale of wealth and capital mobility TXTM now commands. And it doesn’t stop at seeds. The same genetic and biological replication technology can be applied to virtually any seed or biological asset, securing supply chains across industries. Beyond that, TXTM has made clear its intention to expand into precious metals like copper, CBD, hemp-derived products, and other real-world assets. At its core, TXTM is not just a biotech play, it is a real-world asset engine.
________________________________________
That’s The Truth About TXTM
Now investors face a critical decision. You can sit back and wait for the PCAOB audits to confirm everything laid out here, facts already in filings, backed by law, valuation reports, and accounting standards. Remember, the PCAOB exists for one purpose: to ensure companies aren’t committing fraud. That’s it. And when their stamp of approval lands, it will remove the last refuge of doubt.
Or you can look at the history of the last three years. Every foundational tweet from Dr. J, mocked at first, has migrated into filings and become fact. He has never lied. He has the wealth, resources, distribution model, import/export permits, patents, geneticists, lawyers, SEC counsel, and accountants in IFRS and PCAOB, the full infrastructure to guarantee that this model is both compliant and truthful.
This is not just a company. TXTM is the equivalent of a sovereign wealth nation partner, with the power and innovation of a state like California operating within it. Leeds, through Dr. J, has created a model where four seeds out of three thousand per plant come back into TXTM’s hands, turning what looks like a simple contract into a multi-billion-dollar wealth engine. And that valuation is based only on the seeds. It does not yet account for cannabinoid extracts, biomass contracts, or future licensing revenues.
Another critical point we must remember is that Dr. J has already confirmed on X that the cannabinoid extract valuation has been completed, and that the original contracts and revenue streams tied to it remain intact. These revenues are slated to be delivered to TXTM in the future. In addition, advances in bioavailability have been seen as well, further strengthening the company’s scientific and commercial foundation.

Along with his other prior statements that later appeared in the filings, I fully expect these claims to be added to the official record at the appropriate time. Given Dr. J’s track record of stating material facts publicly and then substantiating them in subsequent filings, the evidence is overwhelming that these too are factual. Until I see verified proof to the contrary, I will not contest them, and I expect that the CBD shipments and resulting cannabinoid revenues will be properly reflected in our filings when due.

So investors must choose: continue believing in the dwindling lies, vagueness, and speculation of the past, or believe the filings, the valuations, and the legal framework that prove the truth right now. Once PCAOB verifies what is already known, the game is over. TXTM will not be sitting at fractions of a penny. It will be trading in whole dollars, with no debt, multiplying assets by the billions, and standing as a multi-billion-dollar, debt-free wealth engine unlike anything modern markets have seen.

If comparisons to leading global companies make you uncomfortable, remember this: every figure cited here is drawn directly from TXTM’s current filings and supporting documents. Once the pending filings are submitted through a PCAOB firm, the record will speak for itself. TXTM, as it stands today, is one of, if not the most undervalued stock in the market. And just like every other giant I’ve referenced here, the market will eventually correct the price.

The current share price, sitting at $0.0050 or lower, is insignificant to me. My focus isn’t on the daily ticker, it’s on the underlying company. What matters are the mechanics and structure of TXTM, and its ability to execute on a uniquely complex business model. Over the past three years, I’ve conducted extensive research, and my conclusion is clear: the time will come when the market recognizes what this company truly is. When the right eyes are on it, the market will finally see what we, as investors, have already known all along.

Congratulations to all the investors who have seen this before the world does.
As always, my opinions and should be taken as such.
GLTU